Oct. 24 at 6:41 PM
Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study - PubMed
$ATNM I’m sure Atnm will lap Novartis, J and J, Sanofli, and other big pharma that already funding Act 225 and prostate trials https://pubmed.ncbi.nlm.nih.gov/38218192/